Vavassori Andrea, Jereczek-Fossa Barbara Alicja, Beltramo Giancarlo, De Cicco Luigi, Fariselli Laura, Bianchi Livia Corinna, Possanzini Marco, Bergantin Achille, DeCobelli Ottavio, Orecchia Roberto
Department of Radiotherapy, European Institute of Oncology Milan, Italy.
Tumori. 2010 Jan-Feb;96(1):71-5. doi: 10.1177/030089161009600112.
Technological advances in treatment planning and execution are providing new potential opportunities in the treatment of recurrent prostate cancer. This study was conducted to evaluate the feasibility and safety of reirradiation with image-guided radiosurgery using CyberKnife, a robotic arm-driven compact linear accelerator, for intraprostatic recurrence after external beam radiotherapy (EBRT).
Between September 2007 and May 2008, 6 patients diagnosed with locally recurrent prostate cancer after EBRT were treated using the CyberKnife system. The total reirradiation dose was 30 Gy in five fractions. Prior to radiosurgery four patients were treated with androgen-deprivation therapy. Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and the Houston-Phoenix definition (PSA nadir + 2 ng/mL) were used for toxicity and biochemical failure evaluation, respectively.
After a median follow-up of 11.2 months (range, 9.6-18.6 months), all patients are alive with no evidence of severe urinary or rectal acute morbidity. Local control cannot be exactly determined due to the short follow-up and the bias of the use of androgen ablation. Four patients had biochemical failure, three of them with clinical failure evidence (lymph node, bone and lung metastasis, respectively): none of these patients had clinical evidence of tumor persistence in the prostate.
Salvage radiosurgery with CyberKnife after irradiation is feasible with low urinary and rectal morbidity. A longer follow-up and a larger number of patients are necessary to evaluate its effectiveness and optimal patient selection criteria.
治疗计划与实施方面的技术进步为复发性前列腺癌的治疗提供了新的潜在机会。本研究旨在评估使用射波刀(一种由机器人手臂驱动的紧凑型直线加速器)进行图像引导放射外科再程放疗治疗外照射放疗(EBRT)后前列腺内复发的可行性和安全性。
2007年9月至2008年5月期间,6例经EBRT后诊断为局部复发性前列腺癌的患者接受了射波刀系统治疗。再程放疗总剂量为30 Gy,分5次给予。在进行放射外科治疗前,4例患者接受了雄激素剥夺治疗。分别采用放射治疗肿瘤学组/欧洲癌症研究与治疗组织标准和休斯顿-凤凰城定义(PSA最低点+2 ng/mL)评估毒性和生化失败情况。
中位随访11.2个月(范围9.6 - 18.6个月)后,所有患者均存活,无严重泌尿系统或直肠急性并发症的证据。由于随访时间短以及使用雄激素消融存在偏差,无法准确确定局部控制情况。4例患者出现生化失败,其中3例有临床失败证据(分别为淋巴结、骨和肺转移):这些患者均无前列腺内肿瘤持续存在的临床证据。
放疗后使用射波刀进行挽救性放射外科治疗是可行的,泌尿系统和直肠并发症发生率低。需要更长时间的随访和更多患者来评估其有效性和最佳患者选择标准。